n recent years, drug companies have leveraged research into the molecular makeup of cancer cells to develop highly effective medicines for patients with specific genetic defects. The latest entry in that category: A once-a-day pill from Ignyta (RXDX). It targets defective cancer-causing genes, called ROS1, found in approximately 2 percent of lung cancer cases.

The Ignyta drug, known as entrectinib, is producing large and durable tumor responses that reach into the brain, where ROS1-positive lung cancers commonly spread, according to preliminary clinical trial results presented Tuesday at a research meeting in Japan.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.